Size: | Price | Quantity | |
---|---|---|---|
5 mg | $50.00 | ||
25 mg | $170.00 |
SA4503 (165377-44-6) is a potent and selective sigma-1 agonist (σ1 IC50 = 17.4 nM, σ2 IC50 = 1784 nM).1 It has been investigated as a cognition enhancer2,3, antidepressant4,5, anti-addiction agent6, and neuroprotectant7-10.
References/Citations:
1) Matsuno et al. (1996), Binding properties of SA4503, a novel and selective sigma 1 receptor agonist; Eur. J. Pharmacol. 306 271
2) Matsuno et al. (1997), SA4503, a novel cognition enhancer with sigma 1 agonistic properties; Behav. Brain Res. 83 221
3) Niitsu et al. (2012), Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases; Curr. Pharm. Des. 18 875
4) Skuza and Rogoz et al. (2002), A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist; Behav. Pharmacol. 13 537
5) Lucas et al. (2008), Further evidence for an antidepressant potential of the selective sigma1 agonist SA4503: electrophysiological, morphological and behavioral studies; Int. J. Neuropsychopharmacol. 11 485
6) Mori et al. (2014), Inhibitory effects of SA4503 on the rewarding effects of abused drugs; Addict. Biol. 19 362
7) Nakazawa et al. (1998), Activation of sigma1 receptor subtype leads to neuroprotection in the rat primary neuronal cultures; Neurochem. Int. 32 337
8) Ruscher et al. (2011), The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke; Brain 134(Pt.3) 732
9) Ruscher et al. (2012), Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride on inflammation after stroke; PLoS One. 7 e45118
10) Yamashita et al. (2015), Neuroprotective effects of cutamesine, a ligand of the sigma-1 receptor chaperone, against noise-induced hearing loss; Int. J. Neurosci. Res. 93 788
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
SA4503 (165377-44-6) is a potent and selective sigma-1 agonist (σ1 IC50 = 17.4 nM, σ2 IC50 = 1784 nM).1 It has been investigated as a cognition enhancer2,3, antidepressant4,5, anti-addiction agent6, and neuroprotectant7-10.
References/Citations:
1) Matsuno et al. (1996), Binding properties of SA4503, a novel and selective sigma 1 receptor agonist; Eur. J. Pharmacol. 306 271
2) Matsuno et al. (1997), SA4503, a novel cognition enhancer with sigma 1 agonistic properties; Behav. Brain Res. 83 221
3) Niitsu et al. (2012), Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases; Curr. Pharm. Des. 18 875
4) Skuza and Rogoz et al. (2002), A potential antidepressant activity of SA4503, a selective sigma 1 receptor agonist; Behav. Pharmacol. 13 537
5) Lucas et al. (2008), Further evidence for an antidepressant potential of the selective sigma1 agonist SA4503: electrophysiological, morphological and behavioral studies; Int. J. Neuropsychopharmacol. 11 485
6) Mori et al. (2014), Inhibitory effects of SA4503 on the rewarding effects of abused drugs; Addict. Biol. 19 362
7) Nakazawa et al. (1998), Activation of sigma1 receptor subtype leads to neuroprotection in the rat primary neuronal cultures; Neurochem. Int. 32 337
8) Ruscher et al. (2011), The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke; Brain 134(Pt.3) 732
9) Ruscher et al. (2012), Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride on inflammation after stroke; PLoS One. 7 e45118
10) Yamashita et al. (2015), Neuroprotective effects of cutamesine, a ligand of the sigma-1 receptor chaperone, against noise-induced hearing loss; Int. J. Neurosci. Res. 93 788
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.